Activity of Antioxidant Protection Enzymes in Blood as a Marker of Nephroprotective Effect by Sodium Poly-(2,5-Dihydroxyphenylen)-4-Thiosulfate Acid

Abstract

M., Kostenko V.O. Key words: systemic inflammatory response, acute gingivitis, modulators of redox-sensitive transcription factors NF-κB and Nrf2, quercetin, epigallocatechin-3-gallate, carbohydrate and lipid metabolism.The experiment on 70 white rats was designed to investigate the effects of a water-soluble form of quercetin and modulators of AP-1 and Nrf2 transcription factors on the blood indicators of the systemic inflammatory response (SIR), and carbohydrate and lipid metabolism under the conditions of intraperitoneal and intra-gingival administration of S. typhi lipopolysaccharide (LPS). The animals were divided into 7 groups: the 1st group consisted of intact rats; the 2nd group included animals exposed to combined systemic and local administration of LPS -pyrogenal; the 3rd, 4th and 5th groups included the animals who were respectively injected with watersoluble complex of quercetin and polyvinylpyrrolidone (corvitin) in a dose of 100 mg/kg (10 mg/kg in terms of quercetin), an inhibitor of activation of AP-1 SR 11302 (in a dose of 1 mg / kg) and Keap1 / Nrf2 / antioxidantresponsive element (ARE) signaling pathway inducer epigallocatechin-3-gallate (EGCG, in a dose of 21.1 mg / kg) 3 times a week, starting on the 30 th day since the experiment modeling. The 6th and 7th groups of the rats were subjected to combined effects of quercetin + SR 11302 and quercetin + EGCG, respectively. The study has demonstrated the combination of quercetin and SR 11302, or EGCG, in systemic and local administration of S. typhi lipopolysaccharide more effectively prevents the production of ceruloplasmin, a SIR marker, byproducts of lipid peroxidation in rats' blood, as well as increases its antioxidant potential compared to the separate application of these drugs. The combination of quercetin and SR 11302, or EGCG, under the experimental conditions has been found out to more effectively correct carbohydrate metabolism disorders (hyperinsulinemia, insulin resistance) than this occurs under separate usage of the agents, but does not reveal significant synergism in the correction of dyslipoproteinemia.